{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:49:52Z","timestamp":1792514992112,"version":"4.5.0"},"reference-count":41,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n               <jats:title>Background<\/jats:title>\n               <jats:p>We aimed to construct a novel epithelial-mesenchymal transition (EMT)-related gene pairs (ERGPs) signature to predict overall survival (OS) in skin cutaneous melanoma (CM) patients.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Methods<\/jats:title>\n               <jats:p>Expression data of the relevant genes, corresponding clinicopathological parameters, and follow-up data were obtained from The Cancer Genome Atlas database. Univariate Cox regression analysis was utilized to identify ERGPs significantly associated with OS, and LASSO analysis was used to identify the genes used for the construction of the ERGPs signature. The optimal cutoff value determined by the receiver operating characteristic curve was used to classify patients into high-risk and low-risk groups. Survival curves were generated using the Kaplan\u2013Meier method, and differences between the two groups were estimated using the log-rank test. The independent external datasets <jats:uri xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE65904\">GSE65904<\/jats:uri> and <jats:uri xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE19234\">GSE19234<\/jats:uri> were used to verify the performance of the ERGPs signature using the area under the curve (AUC) values. In addition, we also integrated clinicopathological parameters and risk scores to develop a nomogram that can individually predict the prognosis of patients with CM.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Results<\/jats:title>\n               <jats:p>A total of 104 ERGPs related to OS were obtained, of which 21 ERGPs were selected for the construction of the signature. All CM patients were stratified into high-and low-risk groups based on an optimal risk score cutoff value of 0.281. According to the Kaplan\u2013Meier analysis, the mortality rate in the low-risk group was lower than that in the high-risk group in the TCGA cohort (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001), <jats:uri xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE65904\">GSE65904<\/jats:uri> cohort (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.006), and <jats:uri xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE19234\">GSE19234<\/jats:uri> cohort (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.002). Multivariate Cox regression analysis indicated that our ERGP signature was an independent risk factor for OS in CM patients in the three cohorts (for TCGA: HR, 2.560; 95% CI [1.907\u20133.436]; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001; for <jats:uri xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE65904\">GSE65904<\/jats:uri>: HR = 2.235, 95% CI [1.492\u20133.347], <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001; for <jats:uri xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE19234\">GSE19234<\/jats:uri>: HR = 2.458, 95% CI [1.065\u20135.669], <jats:italic>P<\/jats:italic>\u00a0=\u00a00.035). The AUC value for predicting the 5-year survival rate of patients with CM of our developed model was higher than that of two previously established prognostic signatures. Both the calibration curve and the C-index (0.752, 95% CI [0.678\u20130.826]) indicated that the developed nomogram was highly accurate. Most importantly, the decision curve analysis results showed that the nomogram had a higher net benefit than that of the American Joint Committee on Cancer stage system.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Conclusion<\/jats:title>\n               <jats:p>Our study established an ERGPs signature that could be potentially used in a clinical setting as a genetic biomarker for risk stratification of CM patients. In addition, the ERGPs signature could also predict which CM patients will benefit from PD-1 and PD-L1 inhibitors.<\/jats:p>\n            <\/jats:sec>","DOI":"10.7717\/peerj.12646","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T08:34:48Z","timestamp":1642754088000},"page":"e12646","source":"Crossref","is-referenced-by-count":3,"title":["Identification and validation of an epithelial mesenchymal transition-related gene pairs signature for prediction of overall survival in patients with skin cutaneous melanoma"],"prefix":"10.7717","volume":"10","author":[{"given":"Yucang","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Plastic Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanpeng","family":"Li","sequence":"additional","affiliation":[{"name":"Graduate School of Guangdong Medical University, Zhanjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Graduate School of Guangdong Medical University, Zhanjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simu","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[{"name":"Graduate School of Guangdong Medical University, Zhanjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasheng","family":"Yin","sequence":"additional","affiliation":[{"name":"Graduate School of Guangdong Medical University, Zhanjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Longhua District People\u2019s Hospital, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilan","family":"Weng","sequence":"additional","affiliation":[{"name":"Graduate School of Guangdong Medical University, Zhanjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"10.7717\/peerj.12646\/ref-1","doi-asserted-by":"publisher","first-page":"e173\u2013180","DOI":"10.1016\/s1470-2045(14)71116-7","article-title":"Nomograms in oncology: more than meets the eye","volume":"16","author":"Balachandran","year":"2015","journal-title":"The Lancet Oncology"},{"key":"10.7717\/peerj.12646\/ref-2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1188\/15.Cjon.430-432","article-title":"Nivolumab: immunotherapy in malignant melanoma","volume":"19","author":"Bayless","year":"2015","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"10.7717\/peerj.12646\/ref-3","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jdermsci.2016.12.006","article-title":"Melanoma long non-coding RNA signature predicts prognostic survival and directs clinical risk-specific treatments","volume":"85","author":"Chen","year":"2017","journal-title":"Journal of Dermatological Science"},{"key":"10.7717\/peerj.12646\/ref-4","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/jdv.15487","article-title":"Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of dermatology and venereology task forces on quality of life and patient oriented outcomes, melanoma and non-melanoma skin cancer","volume":"33","author":"Chernyshov","year":"2019","journal-title":"Journal of the European Academy of Dermatology & Venereology"},{"key":"10.7717\/peerj.12646\/ref-5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061566","article-title":"Cutaneous Melanoma-A long road from experimental models to clinical outcome: a review","volume":"19","author":"Coricovac","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.7717\/peerj.12646\/ref-6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Experimental & Molecular Medicine"},{"key":"10.7717\/peerj.12646\/ref-7","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1186\/s12885-020-07391-2","article-title":"Development and validation of a novel pseudogene pair-based prognostic signature for prediction of overall survival in patients with hepatocellular carcinoma","volume":"20","author":"Du","year":"2020","journal-title":"BMC Cancer"},{"key":"10.7717\/peerj.12646\/ref-8","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.91438","article-title":"Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients","volume":"2","author":"Gross","year":"2017","journal-title":"JCI Insight"},{"key":"10.7717\/peerj.12646\/ref-9","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20201704","article-title":"Data mining of immune-related prognostic genes in metastatic melanoma microenvironment","volume":"40","author":"Han","year":"2020","journal-title":"Bioscience Reports"},{"key":"10.7717\/peerj.12646\/ref-10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(sici)1097-0258(19960229)15:4<361::Aid-sim168>3.0.Co;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell Jr","year":"1996","journal-title":"Statistics in Medicine"},{"key":"10.7717\/peerj.12646\/ref-11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nature Reviews Cancer"},{"key":"10.7717\/peerj.12646\/ref-12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nmeth.2445","article-title":"Gene-pair expression signatures reveal lineage control","volume":"10","author":"Hein\u00e4niemi","year":"2013","journal-title":"Nature Methods"},{"key":"10.7717\/peerj.12646\/ref-13","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/s0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.7717\/peerj.12646\/ref-14","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.omtn.2020.10.002","article-title":"Immune-Related lncRNA to construct novel signature and predict the immune landscape of human hepatocellular carcinoma","volume":"22","author":"Hong","year":"2020","journal-title":"Molecular Therapy - Nucleic Acids"},{"key":"10.7717\/peerj.12646\/ref-15","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.2353\/ajpath.2009.080543","article-title":"Gab2-mediated signaling promotes melanoma metastasis","volume":"174","author":"Horst","year":"2009","journal-title":"American Journal of Pathology"},{"key":"10.7717\/peerj.12646\/ref-16","doi-asserted-by":"publisher","first-page":"8186","DOI":"10.1002\/cam4.3438","article-title":"Development of an IFN \u03b3 response-related signature for predicting the survival of cutaneous melanoma","volume":"9","author":"Hu","year":"2020","journal-title":"Cancer Medicine"},{"key":"10.7717\/peerj.12646\/ref-17","doi-asserted-by":"publisher","first-page":"107162","DOI":"10.1016\/j.intimp.2020.107162","article-title":"Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma","volume":"89","author":"Hu","year":"2020","journal-title":"International Immunopharmacology"},{"key":"10.7717\/peerj.12646\/ref-18","doi-asserted-by":"publisher","first-page":"e925494","DOI":"10.12659\/msm.925494","article-title":"Development and validation of a novel immune-gene pairs prognostic model associated with CTNNB1 alteration in hepatocellular carcinoma","volume":"26","author":"Huo","year":"2020","journal-title":"Medical Science Monitor"},{"key":"10.7717\/peerj.12646\/ref-19","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw144","article-title":"Genomic analysis of immune cell infiltrates across 11 tumor types","volume":"108","author":"Iglesia","year":"2016","journal-title":"Journal of the National Cancer Institute"},{"key":"10.7717\/peerj.12646\/ref-20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12938-020-00812-0","article-title":"Development and validation of a RNA binding protein gene pair-associated prognostic signature for prediction of overall survival in hepatocellular carcinoma","volume":"19","author":"Kang","year":"2020","journal-title":"BioMedical Engineering OnLine"},{"key":"10.7717\/peerj.12646\/ref-21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10549-020-05955-1","article-title":"The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer","volume":"185","author":"Kariri","year":"2020","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.7717\/peerj.12646\/ref-22","doi-asserted-by":"publisher","first-page":"6055","DOI":"10.1038\/onc.2015.54","article-title":"ECM1 regulates tumor metastasis and CSC-like property through stabilization of \u03b2-catenin","volume":"34","author":"Lee","year":"2015","journal-title":"Oncogene"},{"key":"10.7717\/peerj.12646\/ref-23","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nrg2825","article-title":"Tackling the widespread and critical impact of batch effects in high-throughput data","volume":"11","author":"Leek","year":"2010","journal-title":"Nature Reviews Genetics"},{"key":"10.7717\/peerj.12646\/ref-24","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/jamaoncol.2017.1609","article-title":"Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer","volume":"3","author":"Li","year":"2017","journal-title":"JAMA Oncology"},{"key":"10.7717\/peerj.12646\/ref-25","doi-asserted-by":"publisher","first-page":"8509805","DOI":"10.1155\/2020\/8509805","article-title":"Development and validation of the B cell-associated Fc receptor-like molecule-based prognostic signature in skin cutaneous melanoma","volume":"2020","author":"Liu","year":"2020","journal-title":"BioMed Research International"},{"key":"10.7717\/peerj.12646\/ref-26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10549-011-1620-1","article-title":"The prognostic significance of B lymphocytes in invasive carcinoma of the breast","volume":"132","author":"Mahmoud","year":"2012","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.7717\/peerj.12646\/ref-27","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/pin.12351","article-title":"Overexpression of adenylate cyclase-associated protein 2 is a novel prognostic marker in malignant melanoma","volume":"65","author":"Masugi","year":"2015","journal-title":"Pathology International"},{"key":"10.7717\/peerj.12646\/ref-28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMra052166","article-title":"Melanoma","volume":"355","author":"Miller","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.7717\/peerj.12646\/ref-29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12022-013-9272-9","article-title":"The role of epithelial mesenchymal transition markers in thyroid carcinoma progression","volume":"24","author":"Montemayor-Garcia","year":"2013","journal-title":"Endocrine Pathology"},{"key":"10.7717\/peerj.12646\/ref-30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1146\/annurev-cellbio-092910-154036","article-title":"The ins and outs of the epithelial to mesenchymal transition in health and disease","volume":"27","author":"Nieto","year":"2011","journal-title":"Annual Review of Cell and Developmental Biology"},{"key":"10.7717\/peerj.12646\/ref-31","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMoa051424","article-title":"Effector memory T cells, early metastasis, and survival in colorectal cancer","volume":"353","author":"Pag\u00e8s","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.7717\/peerj.12646\/ref-32","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/onc.2009.416","article-title":"Immune infiltration in human tumors: a prognostic factor that should not be ignored","volume":"29","author":"Pag\u00e8s","year":"2010","journal-title":"Oncogene"},{"key":"10.7717\/peerj.12646\/ref-33","first-page":"13","article-title":"Your patient with melanoma: staging, prognosis, and treatment","volume":"23","author":"Rubin","year":"2009","journal-title":"Oncology (Williston Park)"},{"key":"10.7717\/peerj.12646\/ref-34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13073-019-0647-5","article-title":"Prognostic value of B cells in cutaneous melanoma","volume":"11","author":"Selitsky","year":"2019","journal-title":"Genome Medicine"},{"key":"10.7717\/peerj.12646\/ref-35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11864-003-0020-0","article-title":"Melanoma: adjuvant therapy and other treatment options","volume":"4","author":"Terando","year":"2003","journal-title":"Current Treatment Options in Oncology"},{"key":"10.7717\/peerj.12646\/ref-36","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.7717\/peerj.12646\/ref-37","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.devcel.2008.05.009","article-title":"Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis","volume":"14","author":"Yang","year":"2008","journal-title":"Developmental Cell"},{"key":"10.7717\/peerj.12646\/ref-38","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s12032-013-0697-2","article-title":"EMT transcription factors: implication in osteosarcoma","volume":"30","author":"Yang","year":"2013","journal-title":"Medical Oncology"},{"key":"10.7717\/peerj.12646\/ref-39","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.tcb.2015.07.012","article-title":"Epithelial-mesenchymal plasticity: a central regulator of cancer progression","volume":"25","author":"Ye","year":"2015","journal-title":"Trends in Cell Biology"},{"key":"10.7717\/peerj.12646\/ref-40","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/cncr.25838","article-title":"Prognostic significance of RUNX3 expression in human melanoma","volume":"117","author":"Zhang","year":"2011","journal-title":"Cancer"},{"key":"10.7717\/peerj.12646\/ref-41","doi-asserted-by":"publisher","first-page":"6419","DOI":"10.1158\/1078-0432.Ccr-13-0254","article-title":"JMJD2B promotes epithelial-mesenchymal transition by cooperating with \u03b2-catenin and enhances gastric cancer metastasis","volume":"19","author":"Zhao","year":"2013","journal-title":"Clinical Cancer Research"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/12646.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/12646.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/12646.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/12646.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T08:34:55Z","timestamp":1642754095000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/12646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":41,"alternative-id":["10.7717\/peerj.12646"],"URL":"https:\/\/doi.org\/10.7717\/peerj.12646","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"article-number":"e12646"}}